The a2 Milk Company Limited logo

Trading update & FY20 Outlook

Full Year Results21 April 2020ATMConsumer Staples

NZX Code: ATM
ASX Code: A2M


The a2 Milk Company Limited

www.thea2milkcompany.com


22 April 2020

NZX/ASX Market Release



Trading update & FY20 Outlook


The a2 Milk Company provided its last update on the Group’s trading performance and its full year FY20

outlook with the release of its interim FY20 results (1H20) on 27 February 2020.

Since then, the Company has continued to experience strong revenue growth across all key regions,

particularly in respect of infant nutrition products sold in China and Australia.

We are now able to confirm that our revenue for the three months to 31 March 2020 (3Q20) was above

expectations. This primarily reflected the impact of changes in consumer purchase behaviour arising from

the COVID-19 situation and included an increase in pantry stocking of our products particularly via online

and reseller channels. We are unable to estimate the timing and extent to which pantry stocking may

unwind.

In addition, our China segment revenue, transacted in US dollars, was favourably impacted by a significant

depreciation of the New Zealand dollar to the US dollar in the quarter.

Overhead costs are now tracking lower than previously expected due to travel restrictions and some

planned recruitment, particularly in China, being temporarily delayed.

The health and wellbeing of our people and those of our partners remains our primary focus and we

continue to take measures to ensure all employees are as safe as possible.

Our business has benefited from the support of all our strategic partners who have assisted in managing

the various supply chain challenges which have arisen during recent months.

We support the actions of the various governments in the countries in which we operate in responding to

the COVID-19 pandemic. We will continue to closely monitor the situation and remain vigilant to the

ongoing advice of authorities.

FY20 Outlook

Given the COVID-19 situation, the outlook for both revenue and earnings remains uncertain. Furthermore,

significant uncertainty remains around the potential impact on supply chains and consumer demand in our

core markets and the resulting financial impact on our performance for the balance of the financial year.

Overall for FY20, we anticipate ongoing revenue growth across our key regions supported by increased

levels of marketing investment in China and the USA as well as, to the extent practicable in the current

circumstances, the ongoing development of our organisational capability to support the execution of our

strategy.



2

Notwithstanding this uncertainty, we anticipate revenue for FY20 in the range of $1,700 million to

$1,750 million.

Full year EBITDA margin is now anticipated to be above that advised in February and in the range of

31% to 32%. This assumes that planned marketing activity for FY20 of $200 million, weighted to 2H20, will

be fully expended prior to year-end.

Our 2H20 EBITDA margin is therefore expected to be higher than previously anticipated. This is primarily a

result of:

• Higher revenue, and hence gross margin, from higher margin nutritional products, in part due to

consumer pantry stocking in 3Q20 compared to expectations;

• Favourable impact arising from exchange rate movement in USD:NZD impacting on China segment

revenue and earnings; and

• Lower than expected costs for travel, and other costs as a consequence of a delay in planned

recruitment, due to COVID-19 restrictions.

It is unlikely that these factors will be sustained as these unprecedented circumstances begin to unwind.

Given the above, the Board continues to consider it appropriate that the Company target an EBITDA margin

in the order of 30% in the medium-term. This assumes the market performance and mix of our products

remains broadly consistent and the competitive environment evolves as anticipated. We will keep the

balance between growth and investment under constant review.


Geoffrey Babidge

Chief Executive Officer

The a2 Milk Company Limited


For further information, please contact:

Investors / Analysts

David Akers

Head of Investor Relations

M +61 412 944 577

david.akers@a2milk.com



Media

Rick Willis

M +61 411 839 344

rick@networkfour.com.au

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • SML — Synlait Milk Limited: Synlait publishes Half Year 2020 Result
    2020-03-18

    HALF YEAR RESULTS 2020 SHAREHOLDER NEWSLETTER3 Supporting this growth is our ongoing investment in milk supply and procurement, research and development, manufacturing capability, quality and regulation and logistics services. This investment has earned Synlait its position a…”

  • SML — Synlait Milk Limited: Synlait updates full year 2020 guidance outlook
    2020-02-12

    Synlait Milk Limited · 1028 Heslerton Road, RD13 Rakaia, Canterbury, New Zealand · +643 373 3000 · www.synlait.com NZX: SML ASX: SM1 13 February 2020 Synlait updates full year 2020 guidance outlook Synlait Milk Limited (Synlait) expects its full year 2020 (F…”

  • AFT — AFT Pharmaceuticals Limited: Market Trading Update
    2020-03-10

    AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com Market and media release 10 March 2020 AFT Pharmaceuticals trading updat…”